Immix Biopharma (IMMX) Reiterated at Market Outperform by Citizens After Q4 Result
Tweet Send to a Friend
Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $23.00 price target on Immix Biopharma, Inc. (NASDAQ: IMMX).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
